Clostridium butyricum RH2 ameliorates diarrhea in juvenile mice under continuous antibiotic exposure by modulating gut microbiota and metabolome
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.01976-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Yufeng Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hangzhou Grand Biologic Pharmaceutical Inc., Hangzhou, China. Hauptthemen laut MEDLINE: Clostridium butyricum, Diarrhea, Anti-Bacterial Agents, Gastrointestinal Microbiome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibiotic-associated diarrhea (AAD) is a self-limiting disorder triggered by antibiotic therapy in pediatric populations. Although multiple probiotics are clinically employed for AAD management, the therapeutic efficacy of Clostridium butyricum ( C. butyricum ) in pediatric AAD and its underlying mechanisms remain poorly characterized. This study aimed to establish a juvenile mice model of AAD and investigate the therapeutic potential of oral C. butyricum administration in juvenile mice subjected to continuous antibiotics exposure. We systematically assessed pathological changes in colonic tissue, colitis severity, intestinal epithelial barrier integrity, fecal metabolomic profiles, and gut microbiota diversity. Our analysis demonstrates that C. butyricum ameliorates intestinal inflammation, enhances barrier function by modulating the gut microbiota and its metabolites, and significantly alleviates diarrhea symptoms in juvenile AAD mice. Collectively, these findings indicate that the therapeutic benefits of C. butyricum are closely linked to its ability to tolerate continuous antibiotic exposure, providing a scientific rationale for its co-administration with antibiotics. IMPORTANCE Clostridium butyricum demonstrates significant therapeutic potential for pediatric antibiotic-associated diarrhea (AAD) by dual modulation of gut microbiota and host physiology. This study reveals its capacity to alleviate intestinal inflammation, restore barrier integrity via upregulation of tight junction proteins and mucins, and rebalance gut microbiota linked to key anti-inflammatory metabolites—even under ongoing antibiotic exposure. These findings position C. butyricum as a targeted probiotic therapy for AAD, offering mechanistic insights to advance microbiome-driven interventions for antibiotic-induced diarrhea in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hangzhou Grand Biologic Pharmaceutical Inc., Hangzhou, China.
ORCID-Profile: Yufeng Zhao, Yu Wang
Zitieren
APA
Zhao, Y., Gao, K., Shang, Y., Cheng, S., Ren, Q., Guo, F., & Wang, Y. (2026). Clostridium butyricum RH2 ameliorates diarrhea in juvenile mice under continuous antibiotic exposure by modulating gut microbiota and metabolome. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01976-25
Vancouver
Zhao Y, Gao K, Shang Y, Cheng S, Ren Q, Guo F, et al. Clostridium butyricum RH2 ameliorates diarrhea in juvenile mice under continuous antibiotic exposure by modulating gut microbiota and metabolome. Microbiology Spectrum. 2026. doi:10.1128/spectrum.01976-25
BibTeX
@article{Zhao2026,
author = {Zhao, Yufeng and Gao, Kan and Shang, Yunlong and Cheng, Shen and Ren, Qianlei and Guo, Fengyu and Wang, Yu},
title = {Clostridium butyricum RH2 ameliorates diarrhea in juvenile mice under continuous antibiotic exposure by modulating gut microbiota and metabolome},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.01976-25}
}
EUVIMED